TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32921472
Drug: Step‐28 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step‐28 (8 L/d of milk from d 11 to 28 and then 4 L/d from d 29 to 63)
Study: 32921472
Drug: Step‐56 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step‐56 (8 L/d of milk from d 11 to 56 and 4 L/d from d 57 to 63)
Study: 32921472
Drug: Control (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (8 L/d of milk from d 11 to 63 and abruptly weaned)
Study: 33821935
Drug: TransFORM Body
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransFORM Body Treatment (TFB)
Study: 34479631
Drug: Reduced or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced or interrupted treatment
Study: 34479631
Drug: Stopped treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopped treatment completely
Study: 34479631
Drug: Reasons for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasons for stopping treatment
Study: 32453368
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication reduction (removal of 1 drug), n=282
Study: 32453368
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no medication changes), n=287
Study: 32127890
Drug: Target controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion (TCI) of propofol with an initial target effect‐site concentration of 4mcg/ml, followed by maintenance at 2.5mcg/ml, titrated by 0.5mcg/ml as needed.
Study: 32127890
Drug: Target controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion (TCI) of propofol.
Study: 34508557
Drug: High-dose SM03
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SM03 (3600 mg, 600 mg × 6 infusions at weeks 0, 2, 4, 12, 14, and 16)
Study: 34508557
Drug: Low-dose SM03
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SM03 (2400 mg, 600 mg × 4 infusions at weeks 0, 2, 12, and 14)
Study: 34508557
Drug: High-dose SM03
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SM03
Study: 34508557
Drug: Low-dose SM03
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SM03
Study: 34508557
Drug: SM03 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM03 (both doses)
Study: 36470677
Drug: Fostamatinib (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib (100-150 mg twice a day for 24 weeks)
Study: 35856162
Drug: Terlipressin (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1.3 μg/kg/hour for 24 h)
Study: 34871513
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of nicorandil
Study: 32546247
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (PN) initiated within 24 hours after PICU admission
Study: 32546247
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (PN) withheld for up to 1 week in the PICU
Study: 33963911
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of alteplase
Study: 38677714
Drug: Early antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early antibiotic exposure
Study: 33453456
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1.5 g/6 h)
Study: 32130809
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir and rilpivirine (monthly intramuscular injections)
Study: 32130809
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (standard antiretroviral therapy)
Study: 35559498
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone acetonide (GC group)
Study: 35000582
Drug: Honey medicinal
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey medicinal gel (unheated natural honey)
Study: 34048095
Drug: Dexamethasone treatment
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone treatment for 2 weeks
Study: 33045769
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation (CV; tidal volume of 9‐10 mL/kg predicted body weight with no positive end‐expiratory pressure)
Study: 33045769
Drug: Protective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective ventilation (PV; tidal volume of 6‐8 mL/kg predicted body weight and 5 cmH₂O PEEP)
Study: 34663784
Drug: Yohimbine administration
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine administration
Study: 33857914
Drug: Qing-Chang-Hua-Shi granules
Normalized name: Shi Liu Fruit
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qing-Chang-Hua-Shi granules (125 g/day)
Study: 33857914
Drug: Placebo (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (125 g/day)
Study: 36272243
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel added to the interrupted microdose flare protocol
Study: 34619734
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin 1 g (group 1)
Study: 34619734
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin 1 g with oral amoxicillin 2 g (group 2)
Study: 32161233
Drug: CHX 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHX 0.12% mouthrinse (twice daily, 10 mL rinse for 30 s)
Study: 32161233
Drug: CHX 0.20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHX 0.20% mouthrinse (twice daily, 10 mL rinse for 30 s)
Study: 32161233
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical treatment (Control group)
Study: 32200009
Drug: Combined bleaching
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bleaching (CB) treatment
Study: 33583390
Drug: Sofosbuvir-based therapy
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir-based therapy
Study: 35137022
Drug: Psychological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological interventions to optimize treatment expectations (IA group, n = 30)
Study: 35137022
Drug: Multi-component intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component intervention (IB group, n = 29) with psychological interventions plus additional treatment package
Study: 35501082
Drug: Antianaerobic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianaerobic antibiotics
Study: 34515439
Drug: Saline enemas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline enemas twice daily until normal stooling pattern achieved (Group 1)
Study: 32888740
Drug: Pentavalent vaccine
Normalized name: rotavirus, live, pentavalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent vaccine (Quinvaxem)
Study: 32888740
Drug: Hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent vaccine (Infanrix-hexa)
Study: 32888740
Drug: Pentavalent vaccine
Normalized name: rotavirus, live, pentavalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent vaccine (Quinvaxem) among TT-vaccinated mothers
Study: 34529839
Drug: Flurbiprofen tablets
Normalized name: Flurbiprofen Tablets
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen tablets (FPT)
Study: 32385508
Drug: Intravenous delta-9-tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous delta-9-tetrahydrocannabinol (THC)
Study: 33177437
Drug: Study treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatments (both interventions)
Study: 33025843
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Hyperthermia
Study: 33631065
Drug: Pooled interleukin-6
Normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled interleukin-6 receptor antagonists (tocilizumab and sarilumab)
Study: 32867199
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA supplementation (2.6 g EPA and 1.8 g DHA)
Study: 33561964
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran dietary intervention (30 g over 24 hours for 24 weeks)
Study: 33561964
Drug: Rice powder
Normalized name: White rice powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice powder (control group, 30 g over 24 hours for 24 weeks)
Study: 32186960
Drug: IL-4 gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-4 gene rs2243291 genotype (C/G)
Study: 34526095
Drug: Early pharmacological
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early pharmacological treatment with ibuprofen (administered 24-72 hours postnatal age)
Study: 34526095
Drug: Early pharmacological
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early pharmacological treatment with ibuprofen
Study: 32452128
Drug: Spironolactone (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (median dose 22.5 mg/day)
Study: 32452128
Drug: Placebo (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (median dose 27.5 mg/day)
Study: 35232809
Drug: Tofacitinib (TOF)
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib (TOF) 5 or 10 mg BID
Study: 35232809
Drug: Tofacitinib (TOF)
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib (TOF) 5 mg BID
Study: 35232809
Drug: Tofacitinib (TOF)
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib (TOF) 5 mg BID with methotrexate (MTX)
Study: 35973146
Drug: Biologics fact
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics fact sheet
Study: 32118387
Drug: Interdisciplinary Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary Treatment (INTER)
Study: 34433772
Drug: Personalized opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized opioid tapering plan
Study: 33465342
Drug: High-dose prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prophylactic anticoagulation (either at intermediate or equivalent to therapeutic dose)
Study: 33465342
Drug: High-dose prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prophylactic anticoagulation
Study: 35551374
Drug: Extended-Release Calcifediol
Normalized name: calcifediol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-Release Calcifediol (ERC) treatment (60 μg/day) for 8 weeks
Study: 35551374
Drug: Extended-Release Calcifediol
Normalized name: calcifediol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-Release Calcifediol (ERC) treatment (30 or 60 μg/day)
Study: 35551374
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplements (cholecalciferol or ergocalciferol)
Study: 32303700
Drug: Biologic agents
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic agents with different modes of action
Study: 32303700
Drug: Aminosalicylate therapy
Normalized name: aminosalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminosalicylate therapy
Study: 35845502
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure (SAA) combined with usual care
Study: 35133113
Drug: Bimekizumab self-injection
Normalized name: bimekizumab Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab self-injection using safety syringe
Study: 35133113
Drug: Bimekizumab self-injection
Normalized name: bimekizumab Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab self-injection using auto-injector
Study: 35133113
Drug: Bimekizumab self-injection
Normalized name: bimekizumab Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab self-injection at Baseline (both devices)
Study: 35593915
Drug: Oral delta‐9‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delta‐9‐tetrahydrocannabinol (THC) 7.5 mg
Study: 35593915
Drug: Oral delta‐9‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delta‐9‐tetrahydrocannabinol (THC) 15 mg
Study: 35593915
Drug: THC (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (7.5 mg and 15 mg)
Study: 34766228
Drug: Stachys schtschegleevii
Normalized name: Stachys officinalis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stachys schtschegleevii tea (2.4 g/day SSC + 2.4 g/day black tea)
Study: 34766228
Drug: Placebo (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.4 g/day black tea)
Study: 35023026
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care and anticoagulation therapy
Study: 33729391
Drug: Exercise Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Training (ET) - 3 weekly sessions of aerobic exercise, local strengthening, and stretching exercises (72 sessions over 40±3.9 weeks)
Study: 36096746
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3D virtual reality and hands-on horticultural activities (8-week intervention)
Study: 32056311
Drug: Naltrexone, acamprosate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone, acamprosate, or placebo with combined behavioral intervention or medication management in COMBINE
Study: 32056311
Drug: Social behavior
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social behavior network therapy or motivational enhancement therapy in UKATT
Study: 35410334
Drug: PD-(L)1 blockade
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-(L)1 blockade in patients with brain and adrenal gland metastases
Study: 35410334
Drug: PD-(L)1 blockade
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-(L)1 blockade in PD-L1-positive populations (PD-L1 > 1%)
Study: 35410334
Drug: METscore in
Approvals — FDA: no, EMA: no, PMDA: no
Description: METscore in patients receiving PD-(L)1 blockade
Study: 35410334
Drug: PD-(L)1 blockade
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-(L)1 blockade as first-line treatment in clinical trials
Study: 35410334
Drug: PD-(L)1 blockade
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-(L)1 blockade as first-line treatment in real-world practice
Study: 35410334
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in patients with various metastatic sites
Study: 36302890
Drug: Molecular testing
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular testing and targeted therapy (specific details not provided)
Study: 33803951
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root powder (0.5 g/kg)
Study: 33803951
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root powder (1 g/kg)
Study: 33803951
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root powder (1.5 g/kg)
Study: 33803951
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root powder (0.5, 1, and 1.5 g/kg)
Study: 35354410
Drug: baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: baricitinib 2 mg
Study: 35354410
Drug: baricitinib 1
Normalized name: baricitinib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: baricitinib 1 mg
Study: 35354410
Drug: baricitinib 1
Normalized name: baricitinib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: baricitinib 1 mg and 2 mg
Study: 35354410
Drug: baricitinib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: baricitinib (1 mg and 2 mg)
Study: 35595197
Drug: Increased FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased FSH dosing (300 IU/day for AFC 1-6, 225 IU/day for AFC 7-9)
Study: 35595197
Drug: Standard FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard FSH dosing (150 IU/day)
Study: 35595197
Drug: Increased FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased FSH dosing
Study: 35595197
Drug: Standard FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard FSH dosing
Study: 34005830
Drug: Modified glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified glycoprotein plant extract (blocker) added to polysensitised samples
Study: 36050448
Drug: Trastuzumab (T)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab (T) + chemotherapy
Study: 32161453
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group 1 (H1, 8 mg/day, 2 mg Q6h)
Study: 32161453
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group 2 (H2, 8 mg/day, 4 mg Q12h)
Study: 32161453
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group (L, 4 mg/day, 1 mg Q6h)
Study: 34793687
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - mometasone, 200 μg or 220 μg twice daily
Study: 34793687
Drug: Long-acting muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting muscarinic antagonists (LAMA) - tiotropium, 5 μg daily
Study: 34535755
Drug: Digital Diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Diabetes Intervention (monthly messages through an online health platform)
Study: 35953808
Drug: Switching antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching antipsychotic medication
Study: 35868244
Drug: 1-hour sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour sound therapy
Study: 35868244
Drug: 3-hour sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hour sound therapy
Study: 35868244
Drug: 5-hour sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hour sound therapy
Study: 34275783
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with hydralazine and sodium nitroprusside
Study: 35041634
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg once daily for 30 days
Study: 32979860
Drug: Erythromycin ointment
Normalized name: Erythromycin Ointment
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ointment
Study: 34326841
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Naltrexone (LDN, 3.0–5.0 mg/day)
Study: 34326841
Drug: Ononetin (TRPM3-antagonist)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ononetin (TRPM3-antagonist)
Study: 36474100
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (bLF) 600 mg daily for 90 days
Study: 34803424
Drug: Rg3-enriched Korean
Normalized name: Korean ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rg3-enriched Korean Red Ginseng (Rg3-KRG) + American Ginseng (AG) at 2.25 g/day
Study: 35523395
Drug: Chaiqin Qingning
Normalized name: PYRROLIDINYL DIAMINOPYRIMIDINE OXIDE 33 g in 100 mL / PANAX GINSENG WHOLE 33 g in 100 mL / DIAMINOPYRIMIDINE OXIDE 30 g in 100 mL / NIACINAMIDE 33 g in 100 mL INTRADERMAL LIQUID [QINGLIN ANTI DETACHMENT NURTURING HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaiqin Qingning Capsule (CQQNC)
Study: 35523395
Drug: Qingkailing Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingkailing Capsule (QKLC)
Study: 33907786
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of far-distal orthodontic force
Study: 33907786
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of far-distal orthodontic force
Study: 33907786
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g of far-distal orthodontic force
Study: 33907786
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g of far-distal orthodontic force
Study: 32822287
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib (LAP) plus Trastuzumab (TRAS) plus Aromatase Inhibitor (AI)
Study: 32822287
Drug: Trastuzumab (TRAS)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab (TRAS) plus Aromatase Inhibitor (AI)
Study: 32822287
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib (LAP) plus Aromatase Inhibitor (AI)
Study: 34348226
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (delivered twice weekly for 8 weeks)
Study: 33492872
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal oxygen (50 l min-1 and a 50:50 oxygen to air ratio)
Study: 33492872
Drug: Facemask oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask oxygen (≥ 8 l min-1)